LRRK2 mutations exhibit a variety of pathological characteristics which include α-synuclein, ubiquitin, and tau protein inclusions leading to the suggestion that LRRK2 may be an important upstream modulator of protein aggregation in neurodegenerative disease [1], [4], [5], [11]. The gene discussed is MAPT; the disease is neurodegenerative disease.